D_Evans45: Just to the right of the article:"GlaxoSmithKline is to pay $3bn (£1.9bn) in the largest healthcare fraud settlement in US history."
Nickninja: thomps: it's an interesting shift going on where the big phrarma companies seem to be scaling back their r&d and instead acquiring their next blockbuster drugs from start-ups. anyone with deeper experience in the industry care to weigh in on whether that is a good or bad shift (or if it's even a shift at all)?I'd say it's a bad shift because it's so hard to get ideas funded through other means. But I'm also currently trying to get an industry job with a bioE phd, so I'm not impartial. But they're mainly doing it to try to avoid the risk/cost of early stage R&D. They let academia develop the ideas, startups do the initial GLP level research, and once something looks promising they gobble it up. It's actually a pretty sweet deal if you're a grad student who is lucky enough to get a project that leads to a commercializable product. When you're in the top level of a startup that is bought out you get major bank, and probably a job with the big company.
born_yesterday: I apologize if you knew most of this and I sounded like I was talking down to you.
Danger Avoid Death: I'm not getting worried until the Umbrella Corporation gets involved.
Mr. Potatoass: [www.fileden.com image 355x449]
PonceAlyosha: From who, exactly? When do I get my share of the check?
If you like these links, you'll love
Total accessTotal knowledgeTotal Fark
Sign up for the Fark NotNewsletter!
Links are submitted by members of the Fark community.
When community members submit a link, they also write a custom headline for the story.
Other Farkers comment on the links. This is the number of comments. Click here to read them.
You need to create an account to submit links or post comments.
Click here to submit a link.
Also on Fark
Submit a Link »
Copyright © 1999 - 2017 Fark, Inc | Last updated: Sep 26 2017 03:47:23
Runtime: 0.432 sec (432 ms)